semaglutide removed from shortage list Novo Nordisk expands Wegovy access as FDA bans copies fda removes semaglutide from shortage

Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal conditions like gastroparesis may rule out tirzepatide and similar GLP-1 based therapies

Los agonistas GLP-1 tienen un peso molecular muy alto (3,000-59,000 Daltons), lo que dificulta su penetracin a travs de la barrera cutnea

Fistulas Healing

Side effects are rare but may include minor redness or soreness at the injection site

According to Citeline's Pharmaprojects analysis, the global market for weight loss drugs is expected to grow dramatically from $2.82 billion in 2022 to over $13 billion by 2029